Drugs / WJ05129
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05326035 | Apr 2022 → Dec 2023 | — | Suzhou Junjing BioSciences Co., Ltd. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-02-09 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Regulatory Aurora A 抑制剂 JS112 获得药物临床试验批准通知书 wigenbio.com ↗
Aurora A 抑制剂WJ05129 片（项目代号“JS112”）的临床试验申请获得批准。 |
| 2021-12-01 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Regulatory Aurora A抑制剂JS112获得药物临床试验申请受理通知书 wigenbio.com ↗
Aurora A 抑制剂 WJ05129 片（项目代号“JS112”）的临床试验申请获得受理。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-02-09 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Aurora A 抑制剂 JS112 获得药物临床试验批准通知书 wigenbio.com ↗ |
| 2021-12-01 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Aurora A抑制剂JS112获得药物临床试验申请受理通知书 wigenbio.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WJ05129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05326035 ↗ |